Loading...
XNAS
GNTA
Market cap73mUSD
Jun 06, Last price  
4.00USD
1D
-6.93%
1Q
5.31%
IPO
-64.43%
Name

Genenta Science SPA

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L+221.27%
-4,607,275-5,605,734-5,560,705-3,624,844-11,645,455
CFO
-6m
L-44.31%
-2,490,187-6,044,581-6,958,174-7,418,236-11,205,023-6,240,174

Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
IPO date
Dec 15, 2021
Employees
4
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
11,775
11,044
Unusual Expense (Income)
NOPBT
(11,775)
(11,044)
NOPBT Margin
Operating Taxes
(4,853)
Tax Rate
NOPAT
(11,775)
(6,191)
Net income
(11,645)
221.27%
(3,625)
-34.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
531
BB yield
0.00%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
229
179
116
Net debt
(12,660)
(18,776)
(29,795)
Cash flow
Cash from operating activities
(6,240)
(11,205)
(7,418)
CAPEX
(4)
(27)
Cash from investing activities
6,883
(14,893)
(27)
Cash from financing activities
271
531
FCF
758
(12,464)
(5,896)
Balance
Cash
12,660
18,776
29,795
Long term investments
Excess cash
12,660
18,776
29,795
Stockholders' equity
12,496
20,432
31,138
Invested Capital
229
1,836
1,459
ROIC
ROCE
EV
Common stock shares outstanding
18,217
18,217
Price
4.35
-12.12%
4.95
-10.00%
5.50
-49.82%
Market cap
90,174
-10.00%
100,193
-49.82%
EV
71,398
70,398
EBITDA
45
(11,732)
(11,038)
EV/EBITDA
Interest
2,566
Interest/NOPBT